Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion
ABSTRACT Purpose: To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with macular edema secondary to central retinal vein occlusion (CRVO). Methods: In this prospective, randomized, double-masked, sham-controlled study, 35 patients with macular edema following CRVO were randomized to intravitreal bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the first 6 months of the study. The primary outcome was the incidence rate of ASN at month 6. The secondary outcomes were the mean changes from baseline in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography over time to month 12. Results: ASN developed in 8 (22.86%) eyes, including 5 (62.50%) eyes in the sham group and 3 (37.50%) eyes in the IVTA group, during 12 months of fol low-up (p=0.009). BCVA differed significantly (p<0.05) among the groups only at month 1. CFT did not differ significantly (p<0.05) among the groups over 12 months. NVG required surgery and developed in one eye despite laser treatment. Conclusion: Early treatment with intravitreal antivascular endothelial growth factor therapy decreases the rates of ASN and NVG after CRVO.
Main Authors: | , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Conselho Brasileiro de Oftalmologia
2017
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492017000200097 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0004-27492017000200097 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0004-274920170002000972017-06-01Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusionLucatto,Luiz Filipe AdamiMagalhães-Junior,OctavianoPrazeres,Juliana M. B.Ferreira,Adriano M.Oliveira,Ramon A.Moraes,Nilva S.Hirai,Flávio E.Maia,Mauricio Neovascularization Pathologic Bevacizumab Retinal vein occlusion Macular edema Glaucoma Neovascular ABSTRACT Purpose: To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with macular edema secondary to central retinal vein occlusion (CRVO). Methods: In this prospective, randomized, double-masked, sham-controlled study, 35 patients with macular edema following CRVO were randomized to intravitreal bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the first 6 months of the study. The primary outcome was the incidence rate of ASN at month 6. The secondary outcomes were the mean changes from baseline in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography over time to month 12. Results: ASN developed in 8 (22.86%) eyes, including 5 (62.50%) eyes in the sham group and 3 (37.50%) eyes in the IVTA group, during 12 months of fol low-up (p=0.009). BCVA differed significantly (p<0.05) among the groups only at month 1. CFT did not differ significantly (p<0.05) among the groups over 12 months. NVG required surgery and developed in one eye despite laser treatment. Conclusion: Early treatment with intravitreal antivascular endothelial growth factor therapy decreases the rates of ASN and NVG after CRVO.info:eu-repo/semantics/openAccessConselho Brasileiro de OftalmologiaArquivos Brasileiros de Oftalmologia v.80 n.2 20172017-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492017000200097en10.5935/0004-2749.20170024 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Lucatto,Luiz Filipe Adami Magalhães-Junior,Octaviano Prazeres,Juliana M. B. Ferreira,Adriano M. Oliveira,Ramon A. Moraes,Nilva S. Hirai,Flávio E. Maia,Mauricio |
spellingShingle |
Lucatto,Luiz Filipe Adami Magalhães-Junior,Octaviano Prazeres,Juliana M. B. Ferreira,Adriano M. Oliveira,Ramon A. Moraes,Nilva S. Hirai,Flávio E. Maia,Mauricio Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion |
author_facet |
Lucatto,Luiz Filipe Adami Magalhães-Junior,Octaviano Prazeres,Juliana M. B. Ferreira,Adriano M. Oliveira,Ramon A. Moraes,Nilva S. Hirai,Flávio E. Maia,Mauricio |
author_sort |
Lucatto,Luiz Filipe Adami |
title |
Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion |
title_short |
Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion |
title_full |
Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion |
title_fullStr |
Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion |
title_full_unstemmed |
Incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion |
title_sort |
incidence of anterior segment neovascularization during intravitreal treatment for macular edema secondary to central retinal vein occlusion |
description |
ABSTRACT Purpose: To analyze the effects of injections of intravitreal triamcinolone acetonide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients with macular edema secondary to central retinal vein occlusion (CRVO). Methods: In this prospective, randomized, double-masked, sham-controlled study, 35 patients with macular edema following CRVO were randomized to intravitreal bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the first 6 months of the study. The primary outcome was the incidence rate of ASN at month 6. The secondary outcomes were the mean changes from baseline in best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography over time to month 12. Results: ASN developed in 8 (22.86%) eyes, including 5 (62.50%) eyes in the sham group and 3 (37.50%) eyes in the IVTA group, during 12 months of fol low-up (p=0.009). BCVA differed significantly (p<0.05) among the groups only at month 1. CFT did not differ significantly (p<0.05) among the groups over 12 months. NVG required surgery and developed in one eye despite laser treatment. Conclusion: Early treatment with intravitreal antivascular endothelial growth factor therapy decreases the rates of ASN and NVG after CRVO. |
publisher |
Conselho Brasileiro de Oftalmologia |
publishDate |
2017 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492017000200097 |
work_keys_str_mv |
AT lucattoluizfilipeadami incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion AT magalhaesjunioroctaviano incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion AT prazeresjulianamb incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion AT ferreiraadrianom incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion AT oliveiraramona incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion AT moraesnilvas incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion AT hiraiflavioe incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion AT maiamauricio incidenceofanteriorsegmentneovascularizationduringintravitrealtreatmentformacularedemasecondarytocentralretinalveinocclusion |
_version_ |
1756373233872928768 |